p-tau 205 & p-tau 212 Assays

About Quanterix

Quanterix's mission is to accelerate the understanding of biology and the detection of disease through ultra-sensitive biomarker measurement. Its core achievement is the development and global commercialization of the Simoa platform, which is the gold standard for digital immunoassays, supported by over 5,000 peer-reviewed publications and partnerships with top pharmaceutical companies. The company's strategy is a 'full-spectrum' approach, combining its leading liquid biopsy capabilities with spatial proteomics from Akoya to provide integrated insights from blood to tissue. This positions Quanterix to capture value across the entire biomarker continuum, from research and drug development to clinical diagnostics.

Therapeutic Areas

Other Alzheimer's Disease Research Drugs